Lactobacillus fermentum Inhibits the Development of Colitis by Regulating the Intestinal Microbiota and Metabolites to Enhance the Intestinal Barrier and Decrease Inflammatory Responses

发酵乳杆菌通过调节肠道菌群和代谢产物来增强肠道屏障并减少炎症反应,从而抑制结肠炎的发展。

阅读:2

Abstract

Ulcerative colitis (UC) is a chronic inflammatory disorder difficult to cure with current treatments. Therefore, preventive interventions for UC are crucial. This research investigated the intervention potential of Lactobacillus (L.) fermentum S1 derived from a cat in reducing dextran sulfate sodium (DSS)-triggered UC. Through a combination of physiological, microbiological, and metabolomic analyses, we demonstrated that preventive supplementation with L. fermentum S1 significantly mitigated DSS-triggered body weight loss, colon shortening, intestinal barrier (IB) dysfunction, and inflammatory reaction. L. fermentum S1 modulated gut microbiota (GM) components and elevated short-chain fatty acids generation. Beneficial genera were abundant (Akkermansia, Ligilactobacillus, Turicibacter, and Prevotella_9) while suppressing pathogenic taxa (Parabacteroides and Acinetobacter). Furthermore, L. fermentum S1 increased the amount of the anti-inflammatory metabolite hecogenin within the intestines. Spearman's correlation analysis exhibited significant associations between microbial shifts and metabolite profiles, suggesting that microbiota-derived metabolites can mediate their therapeutic effects. These outcomes indicate the potential of L. fermentum S1 as a new dietary supplement and provide a theoretical basis for UC prevention.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。